Milestone Pharmaceuticals to Present at Upcoming Investor Conferences

Rhea-AI Summary

Milestone Pharmaceuticals (Nasdaq: MIST) announced presentations by CEO Joseph Oliveto at key investor conferences. The 2021 Jefferies London Virtual Healthcare Conference presentation becomes available on-demand on November 18, 2021, at 3:00 a.m. ET. Additionally, at the Piper Sandler 33rd Annual Virtual Healthcare Conference, a fireside chat will be accessible starting at 10:00 a.m. ET on November 22, 2021. Replays will be found on Milestone's website for approximately 30 days after the events, reinforcing their commitment to innovative cardiovascular medicine.

MONTREAL and CHARLOTTE, N.C., Nov. 11, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will present at the following investor conferences:

• The 2021 Jefferies London Virtual Healthcare Conference. The presentation will be available on demand beginning at 3:00 a.m. ET/8:00 a.m. GMT on Thursday, November 18, 2021.
• The Piper Sandler 33^rd Annual Virtual Healthcare Conference. The fireside chat will be available on demand beginning at 10:00 a.m. ET on Monday, November 22, 2021.

A replay of the pre-recorded presentations can be accessed in the News & Events section of Milestone's website at www.milestonepharma.com and will be available on the same website for approximately 30 days following the presentations.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), is a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. Milestone's lead product candidate etripamil is currently in a Phase 3 clinical-stage program for the treatment of paroxysmal supraventricular tachycardia (PSVT) and in a Phase 2 proof-of-concept trial for the treatment of patients with atrial fibrillation and rapid ventricular rate (AFib-RVR). Milestone Pharmaceuticals operates in Canada and the United States. For more information, visit www.milestonepharma.com and follow the Company on Twitter at @MilestonePharma.

Contact

David Pitts
Argot Partners
212-600-1902
david@argotpartners.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/milestone-pharmaceuticals-to-present-at-upcoming-investor-conferences-301421784.html

SOURCE Milestone Pharmaceuticals, Inc.

FAQ

When is Milestone Pharmaceuticals' presentation at the Jefferies London Virtual Healthcare Conference?

Milestone Pharmaceuticals' presentation at the Jefferies London Virtual Healthcare Conference is available on-demand starting November 18, 2021, at 3:00 a.m. ET.

What is the date and time for Milestone Pharmaceuticals' fireside chat at the Piper Sandler Conference?

The fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference is available on-demand starting November 22, 2021, at 10:00 a.m. ET.

Where can I access the replay of Milestone Pharmaceuticals' investor presentations?

Replays of Milestone Pharmaceuticals' investor presentations can be accessed in the News & Events section of their website for about 30 days after the events.

What is the focus of Milestone Pharmaceuticals as mentioned in the press release?

Milestone Pharmaceuticals is focused on the development and commercialization of innovative cardiovascular medicines, including their lead product candidate etripamil.

What are the primary clinical trials being conducted by Milestone Pharmaceuticals?

Milestone Pharmaceuticals is conducting a Phase 3 clinical-stage program for etripamil to treat paroxysmal supraventricular tachycardia (PSVT) and a Phase 2 proof-of-concept trial for atrial fibrillation with rapid ventricular rate (AFib-RVR).